A-Line Medical LogisticsALML · Clinical Supply Platform
Back to Products
Recovery & Performance

ARA-290

ARA-290 is a synthetic peptide based on the helix B domain of erythropoietin, commonly explored in provider-directed programs focused on inflammatory and neuropathic wellness. It should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.

INFLAMMATORY WELLNESSNEUROPATHIC SUPPORTREGENERATIVE WELLNESS

What It Is Used For

Primary Goals & Applications

ARA-290 is commonly considered in provider-directed programs focused on the following areas of interest:

  • Inflammatory Wellness — Often considered in provider-directed programs designed to support inflammatory wellness objectives.

  • Neuropathic Support — May be explored within programs focused on neuropathic and nerve-related wellness goals.

  • Regenerative Wellness — May be considered for patients whose goals include tissue response and regenerative wellness objectives.

ARA-290 should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.

How It Works

Mechanism of Action

ARA-290 is a synthetic peptide based on the helix B domain of erythropoietin, designed to engage tissue-protective pathways without stimulating red-blood-cell production. Areas of biological activity include:

Areas being studied include:

  • Inflammatory Signaling — ARA-290 has been studied for potential effects on biological pathways involved in inflammatory responses.

  • Tissue-Protective Receptor Activity — Preclinical research has investigated interaction with the innate repair receptor, a pathway associated with tissue protection and repair.

  • Neuropathic and Nerve-Related Pathways — Research has explored potential effects on nerve-related processes and neuropathic wellness.

  • Recovery and Regenerative Pathways — Preclinical research has explored potential effects on cellular processes associated with tissue response and recovery.

Clinical use of ARA-290 varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.

Clinical Information

Provider Considerations & Warnings

Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering ARA-290 for a patient.

Include these considerations:

  • Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.

  • Use Within Approved and Appropriate Context — ARA-290 should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.

  • Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors throughout the course of use.

  • Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.

ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.

Available Options

Formulations & Strengths

Option 1

Formulation
ARA-290
Strength
Verification Pending
Availability
Clinic Account

Verified formulations and strengths will be updated based on current pharmacy availability.

Dosing & Reconstitution

Dosing & Reconstitution

Reconstitution Calculator

For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.

Product Dosing Schedule

Daily|mg/day|7 administrations/week

Provider Inputs

Calculated Outputs

Concentration

—

Medication amount ÷ diluent mL

Volume to Draw

—

Desired dose ÷ concentration

U-100 Syringe Units

—

Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL

Reference Dosing

Low / Starting Dose1 mg once daily
Standard Dose2.5 mg once daily
High Dose4 mg once daily
FrequencyDaily
Dose Unitmg/day
Administrations Per Week7

Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.

This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.

Ask ALML

Why Ask ALML May Suggest This Product

Ask ALML may identify ARA-290 as a product for a healthcare professional to explore when the described patient goals involve inflammatory wellness, neuropathic support, or regenerative wellness.

The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.

Interested in this therapy?

Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.

ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.